RIDGEFIELD, Conn. and
INDIANAPOLIS, July 31, 2017 /PRNewswire/ -- Boehringer
Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced
that the companies will support an American College of Cardiology
(ACC) program focused on driving quality improvement in cardiology
and addressing the latest research advances in the reduction of
cardiovascular risk and cardiovascular mortality in people with
type 2 diabetes.
Despite recent advances, cardiovascular disease is still the
leading cause of death associated with diabetes. Given that people
with diabetes are two to four times more likely to develop
cardiovascular disease than people without diabetes, cardiologists
are treating more and more of the 30 million adults in the U.S.
living with this condition who have experienced a cardiovascular
event. Approximately 50 percent of deaths in people with type 2
diabetes worldwide and approximately two-thirds of deaths in people
with type 2 diabetes in the U.S. are caused by cardiovascular
disease.
The new program will capture key learnings from cardiologists
who are managing cardiovascular risk for people with type 2
diabetes and identify how and why these healthcare professional
innovators are leading this challenge. The learnings will be shared
with the wider cardiology community to help prepare them for their
increasingly important responsibility in reducing cardiovascular
morbidity and mortality in people with type 2 diabetes.
"The ACC encourages efforts nationwide and globally to educate
and communicate to cardiovascular healthcare providers and
scientists about innovative advances in cardiovascular risk
reduction in type 2 diabetes. This is the first stage in a
longer-term process of optimizing cardiovascular risk reduction in
these complex patient populations," said Nathan D. Wong, Ph.D., FACC, professor and
director of the Heart Disease Prevention Program, Division of
Cardiology at University of California,
Irvine School of Medicine.
This initiative draws upon the unique power of the Diabetes
Collaborative Registry, along with ACC's unsurpassed expertise in
understanding and driving quality improvement in cardiology, to
prepare the cardiology community for a coming paradigm shift in
type 2 diabetes management and cardiovascular risk reduction. More
information about the ACC's Diabetes Collaborative Registry can be
found at https://www.ncdr.com/WebNCDR/Diabetes/publicpage.
"Along with Lilly, Boehringer Ingelheim is proud to support the
ACC in its efforts to drive quality improvement in cardiology,"
said Thomas Seck, M.D., vice president of Clinical Development and
Medical Affairs – Primary Care, Boehringer Ingelheim
Pharmaceuticals, Inc. "Given recent advances in research on
cardiovascular risk reduction for people with type 2 diabetes, we
need a better understanding of how and when innovative healthcare
professionals are adopting new tools in our efforts to help educate
the wider cardiology community."
Additional information on the latest clinical trial and other
research findings and hot topics relating to the prevention,
assessment, and management of diabetes and cardiovascular disease
can be found on ACC.org under the Diabetes and Cardiometabolic
Clinical Topics Collection at
http://www.acc.org/clinical-topics/diabetes-and-cardiometabolic-disease.
About Diabetes and Cardiovascular Disease
Approximately 30 million Americans and an estimated 415 million
people worldwide have diabetes, and nearly 24 percent of Americans
with diabetes—or more than 7 million people—are undiagnosed. In the
U.S., approximately nine percent of those aged 18 and older have
diabetes. Type 2 diabetes is the most common type, accounting for
an estimated 90 to 95 percent of all diagnosed adult diabetes cases
in the U.S. Diabetes is a chronic condition that occurs when
the body does not properly produce or use the hormone insulin.
Due to the complications associated with diabetes, such as high
blood sugar, high blood pressure and obesity, cardiovascular
disease is a major complication and the leading cause of death
associated with diabetes. People with diabetes are two to four
times more likely to develop cardiovascular disease than people
without diabetes. Approximately 50 percent of deaths in people with
type 2 diabetes worldwide and approximately two-thirds of deaths in
people with type 2 diabetes in the U.S. are caused by
cardiovascular disease. In the U.S., healthcare costs for managing
cardiovascular conditions in patients with diabetes totaled more
than $23 billion in 2012.
Having a history of diabetes at age 60 can shorten a person's
lifespan by as much as six years compared with someone without
diabetes. And having both diabetes and a history of heart attack or
stroke at age 60 can shorten a person's lifespan by as much as 12
years compared with someone without these conditions.
About Educational Initiatives
Given the critical
connection between diabetes and cardiovascular disease, Boehringer
Ingelheim and Eli Lilly and Company are committed to providing
programs and support to raise awareness, understanding and action
toward reducing the impact of cardiovascular disease in people with
type 2 diabetes.
About the American College of Cardiology
The American
College of Cardiology is a 52,000-member medical society that is
the professional home for the entire cardiovascular care team. The
mission of the College is to transform cardiovascular care and to
improve heart health. The ACC leads in the formation of health
policy, standards and guidelines. The College operates national
registries to measure and improve care, offers cardiovascular
accreditation to hospitals and institutions, provides professional
medical education, disseminates cardiovascular research and bestows
credentials upon cardiovascular specialists who meet stringent
qualifications. For more, visit acc.org.
Boehringer Ingelheim and Eli Lilly and Company
In
January 2011, Boehringer Ingelheim
and Eli Lilly and Company announced an alliance in diabetes that
centers on compounds representing several of the largest diabetes
treatment classes. This alliance leverages the strengths of two of
the world's leading pharmaceutical companies. By joining forces,
the companies demonstrate commitment in the care of patients with
diabetes and stand together to focus on patient needs. Find out
more about the alliance at www.boehringer-ingelheim.com or
www.lilly.com.
About Boehringer Ingelheim
Boehringer Ingelheim
Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary
of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's top 20 pharmaceutical
companies. Headquartered in Ingelheim, Germany, the company operates globally with
approximately 50,000 employees. Since its founding in 1885, the
company has remained family-owned and today creates value through
innovation for three business areas including human
pharmaceuticals, animal health and biopharmaceutical contract
manufacturing.
Boehringer Ingelheim is committed to improving lives and
providing valuable services and support to patients and their
families. Our employees create and engage in programs that
strengthen our communities. Please visit our website to learn more
about how we make more health for more people through our Corporate
Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about
$17.6 billion (15.9 billion euros). R&D expenditure
corresponds to 19.6 percent of its net sales.
For more information please visit www.boehringer-ingelheim.us,
or follow us on Twitter @BoehringerUS.
About Lilly Diabetes
Lilly has been a global leader in
diabetes care since 1923, when we introduced the world's first
commercial insulin. Today we are building upon this heritage by
working to meet the diverse needs of people with diabetes and those
who care for them. Through research and collaboration, a wide range
of therapies and a continued determination to provide real
solutions—from medicines to support programs and more—we strive to
make life better for all those affected by diabetes around the
world. For more information, visit www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels.
###
CR-LLY
PC-05129
CONTACT:
Lauren Murphy,
MBA
Associate Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: lauren.murphy@boehringer-ingelheim.com
Phone: (203) 448-1982
Grant
Smith
Communications
Lilly Diabetes
Email: grant.smith@lilly.com
Phone: (317) 954-9907
Nicole Napoli
Associate
Director, Media Relations
American College of Cardiology
Email: nnapoli@acc.org
Phone: (202) 375-6523
View original content with
multimedia:http://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-to-support-new-american-college-of-cardiology-program-to-highlight-the-increasingly-important-role-of-cardiologists-in-reducing-cardiovascular-risk-and-cardiovascular-death-in-people-with-type-2-diab-300496371.html
SOURCE Eli Lilly and Company